Form 4: Guardian Pharmacy CFO Sells Shares Under 10b5-1 Plan

Guardian Pharmacy Services' CFO, David K. Morris, sold 187,855 shares of Class A common stock for approximately $5.58 million under a pre-arranged plan.

Summary

• David K. Morris, Executive Vice President and Chief Financial Officer of Guardian Pharmacy Services, Inc., disposed of 187,855 shares of Class A Common Stock.
• The transaction occurred on March 20, 2026, at a price of $29.6825 per share.
• The total value of the shares sold amounts to approximately $5,579,999.88.
• Following this transaction, Mr. Morris directly beneficially owns 254,472 shares of Class A Common Stock.
• The sale was executed pursuant to an Underwriting Agreement dated March 18, 2026, and was made under a Rule 10b5-1 plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While insider selling can be a concern, the execution under a Rule 10b5-1 plan indicates a pre-scheduled transaction, mitigating the interpretation of a negative signal regarding the company's immediate prospects.

Negatives

• A significant sale of shares by a key executive, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, though this is mitigated by the Rule 10b5-1 plan.

Risks

• Market perception of insider selling could lead to short-term negative pressure on the stock price, despite the pre-planned nature of the transaction.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider selling, particularly by a CFO, can sometimes raise questions about a company's near-term prospects. However, the disclosure that this sale was made pursuant to a Rule 10b5-1 plan suggests it was a pre-arranged transaction for personal financial management, which typically lessens the negative signal compared to an unannounced, opportunistic sale.

Stakeholder Impact

• Shareholders may interpret the insider sale, even if pre-planned, as a data point in their assessment of the company's valuation or future performance. The transparency of the 10b5-1 plan helps manage potential negative sentiment.

Key Dates

Recommendation

The sale by a key executive, while significant in volume, was conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled for personal financial planning rather than a reaction to immediate company prospects. This typically mitigates negative market interpretation, warranting a 'hold' as it doesn't inherently signal a change in the company's fundamental outlook.

Keywords

Guardian Pharmacy Services, GRDN, Insider Sale, Form 4, David K. Morris, Class A Common Stock, 10b5-1 Plan, Executive Vice President, Chief Financial Officer